These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 10607846)

  • 1. Discovery of new anti-cancer agents.
    Lobbezoo MW; Krul MR; Pinedo HM
    Forum (Genova); 1999; 9(3 Suppl 3):47-53. PubMed ID: 10607846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticancer research: a few hints for discovery of new targets.
    Lacal JC
    Cancer Lett; 2004 Apr; 206(2):125-7. PubMed ID: 15013517
    [No Abstract]   [Full Text] [Related]  

  • 4. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
    Workman P
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of molecular computer modeling in anticancer drug development.
    Geromichalos GD
    J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New approaches in metastatic melanoma: biological and molecular targeted therapies.
    Lejeune FJ; Rimoldi D; Speiser D
    Expert Rev Anticancer Ther; 2007 May; 7(5):701-13. PubMed ID: 17492933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telomeres and telomerase as targets for anticancer drug development.
    Olaussen KA; Dubrana K; Domont J; Spano JP; Sabatier L; Soria JC
    Crit Rev Oncol Hematol; 2006 Mar; 57(3):191-214. PubMed ID: 16469501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular basis of therapeutic approaches to gastric cancer.
    Wu K; Nie Y; Guo C; Chen Y; Ding J; Fan D
    J Gastroenterol Hepatol; 2009 Jan; 24(1):37-41. PubMed ID: 19196394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current strategies and future directions of antiangiogenic tumor therapy.
    Zhang ZL; Wang JH; Liu XY
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Oct; 35(10):873-80. PubMed ID: 14515202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel targets for therapy in paediatric oncology.
    Estlin EJ
    Curr Drug Targets Immune Endocr Metabol Disord; 2002 Jul; 2(2):141-50. PubMed ID: 12476788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for prostate cancer - recent progress in clinical trials.
    Kipp RT; McNeel DG
    Clin Adv Hematol Oncol; 2007 Jun; 5(6):465-74, 477-9. PubMed ID: 17679921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New drugs in prostate cancer.
    Armstrong AJ; Carducci MA
    Curr Opin Urol; 2006 May; 16(3):138-45. PubMed ID: 16679849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New approaches to drug discovery and development: a mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent.
    Hausheer FH; Kochat H; Parker AR; Ding D; Yao S; Hamilton SE; Petluru PN; Leverett BD; Bain SH; Saxe JD
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S3-15. PubMed ID: 12819940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of targeted therapy in non-small cell lung cancer.
    Maione P; Rossi A; Airoma G; Ferrara C; Castaldo V; Gridelli C
    Crit Rev Oncol Hematol; 2004 Jul; 51(1):29-44. PubMed ID: 15207252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular-targeted therapies: lessons from years of clinical development.
    Rosa DD; Ismael G; Lago LD; Awada A
    Cancer Treat Rev; 2008 Feb; 34(1):61-80. PubMed ID: 17826917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Development of molecular targeting drugs for the treatment of cancer-therapeutic potential and issues to be addressed in global development].
    Akaza H; Aiba K; Isonishi S; Ogawa O; Shibuya M; Sone S; Tsuruo T; Noguchi S; Hinotsu S; Kono S; Mikami O; Blackledge G; Vose B; Stribling D
    Gan To Kagaku Ryoho; 2000 Oct; 27(11):1681-93. PubMed ID: 11057319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel targets and approaches in advanced prostate cancer.
    Hadaschik BA; Sowery RD; Gleave ME
    Curr Opin Urol; 2007 May; 17(3):182-7. PubMed ID: 17414516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New molecular targets and biological therapies in sarcomas.
    Scappaticci FA; Marina N
    Cancer Treat Rev; 2001 Dec; 27(6):317-26. PubMed ID: 11908925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents.
    Morin MJ
    Oncogene; 2000 Dec; 19(56):6574-83. PubMed ID: 11426642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New science-based endpoints to accelerate oncology drug development.
    Kelloff GJ; Sigman CC
    Eur J Cancer; 2005 Mar; 41(4):491-501. PubMed ID: 15737552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.